{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '620 Memorial Drive',
 'address2': 'Suite 200 West',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.23,
 'askSize': 800,
 'averageDailyVolume10Day': 62475,
 'averageVolume': 121123,
 'averageVolume10days': 62475,
 'beta': 1.003246,
 'beta3Year': None,
 'bid': 3.98,
 'bidSize': 1000,
 'bookValue': 1.217,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.27,
 'dayLow': 4,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.206,
 'enterpriseToRevenue': None,
 'enterpriseValue': 104840808,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.2518573,
 'fiftyTwoWeekHigh': 9.265,
 'fiftyTwoWeekLow': 3.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16125132,
 'forwardEps': -2.32,
 'forwardPE': -1.7327586,
 'fromCurrency': None,
 'fullTimeEmployees': 98,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.0012899999,
 'heldPercentInstitutions': 0.86571,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/evelobio.com',
 'longBusinessSummary': 'Evelo Biosciences, Inc., a biotechnology company, '
                        'focuses on the development of monocolonal microbials '
                        'for the treatment of inflammatory diseases and '
                        'cancer. It is involved in developing EDP1066 and '
                        'EDP1815, which are in Phase 1b placebo-controlled '
                        'dose-escalating safety and tolerability clinical '
                        'study for the treatment of atopic dermatitis, asthma, '
                        'psoriatic arthritis, rheumatoid arthritis, and '
                        'inflammatory bowel diseases. The company is also '
                        'involved in developing EDP150, a monoclonal microbial '
                        'candidate, which is in Phase 1/2 clinical study for '
                        'the treatment of colorectal cancer, triple-negative '
                        'breast cancer, and melanoma, as well as patients who '
                        'have relapsed on prior PD-1/L1 inhibitor treatment '
                        'across multiple tumor types. Evelo Biosciences, Inc. '
                        'was founded in 2014 and is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'Evelo Biosciences, Inc.',
 'market': 'us_market',
 'marketCap': 185454656,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_331329033',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -88214000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.12,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-577-0300',
 'previousClose': 4.16,
 'priceHint': 4,
 'priceToBook': 3.3032045,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.27,
 'regularMarketDayLow': 4,
 'regularMarketOpen': 4.12,
 'regularMarketPreviousClose': 4.16,
 'regularMarketPrice': 4.12,
 'regularMarketVolume': 38644,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 46133000,
 'sharesPercentSharesOut': 0.051799998,
 'sharesShort': 2389117,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1669869,
 'shortName': 'Evelo Biosciences, Inc.',
 'shortPercentOfFloat': 0.097799994,
 'shortRatio': 12.51,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'EVLO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.747,
 'twoHundredDayAverage': 4.5555396,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'fb56bcc1-036c-3103-a1ef-4deb82721e11',
 'volume': 38644,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.evelobio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}